CA1318253C - Stabilized pergolide compositions - Google Patents
Stabilized pergolide compositionsInfo
- Publication number
- CA1318253C CA1318253C CA000580595A CA580595A CA1318253C CA 1318253 C CA1318253 C CA 1318253C CA 000580595 A CA000580595 A CA 000580595A CA 580595 A CA580595 A CA 580595A CA 1318253 C CA1318253 C CA 1318253C
- Authority
- CA
- Canada
- Prior art keywords
- pergolide
- composition
- light
- decomposition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Abstract Pharmaceutical compositions containing pergolide or pharmaceutically-acceptable salts thereof stabilized to decomposition by light by incorporation therewith of a stabilizing agent selected from poly-vinylpyrrolidone, .alpha.-tocopherol succinate and propyl gallate.
Description
13~8~
STABILIZED PERGOLIDE COMPOSITIONS
This invention relates to pharmaceutical compositions containing pergolide.
Pergolide is an ergoline derivative which exhibits potent dopaminergic agonist activity and also decreases plasma prolactin concentrations. The com~ound is thus useful in treating physiological manifestations associated with hyperprolactinemia. Chemically, pergolide is D-6-n-propyl-8~-methylmercaptomethyl-ergoline (See U.S. Patent 4,166,1823.
It has been found that pergolide decomposes upon exposure to light (apparently to a sulfoxide species) thus making it necessary to handle the compound and store the ultimate dosage form in light-controlled environments so as to avoid a demonstrable drop in potency of the therapeutic agent. In order to retard this drop in potency, certain stabilizing agents have been incorporated into pharmaceutical compositions containing pergolide which surprisingly reduce the decomposition of this compound when exposed to light.
The present invention is directed to a pharmaceutical composition o pergolide or pharma-ceutically-acceptable salts thereof stabilized to decomposition by light. Said composition comprises pergolide or pharmaceutically-acceptable salts thereof, a stabilizing agent selected from polyvinylpyrrolidone, a-tocopherol succinate and propyl gallate in an amount , l 3 1 ~
X-637~ -2-sufficient to effect stabilization to decomposition by light, and one or more pharmaceutically acceptable excipients.
Also provided is a method of stabilizing a pharmaceutical composition of pergolide or pharma-ceutical-acceptable salts thereof to decomposition by light. The method comprises incorporating into said pharmaceutical composition, in addition to the pergolide or pharmaceutically-acceptable salts thereof, as well a~ the pharmaceutically acceptable excipients normally present, a stabilizing agent selected from polyvinyl-pyrrolidone, ~-tocopherol succinate and propyl gallate in an amount sufficient to effect stabilization to decomposition by light. Normally, each unit dosage such as a tablet or capsule will contain sufficient pergolide or salt thereof to be therapeutically-effective.
Pergolide (i.e., D-6-n-propyl-8~-methyl-mercaptomethylergoline) may be prepared as described in U.S. Patent 4,166,182. Briefly, methyl dihydrolysergate can be treated with cyanogen bromide in an inert solvent such as chloroform, methylene dichloride, toluene, DMF
and the like to form D-6-cyano-8~-methoxycarbonyl ergoline. The cyanide group is then readily removed as by zinc dust in acetic acid forming a secondary amine function at N-6 which can then be re-alkylated with, for example, N-propyl iodide in an inert, preferably polar solvent such as dimethylformamide or nitromethane at temperatures in the range of 20-50 centigrade (C~. The ester function at C-8 is then reduced by treatmen~ with, if~
~ $~
for example, sodium borohydride in dioxane to formD~6-n-propyl-8~-hydroxymethylergoline which is then re-esterified by treatment with methanesulfonyl chloride in pyridine to form D-6-n-propyl-8~-mesyloxymethyl ergoline. The mesyloxy derivative is then treated with methylmercaptan in dimethyl acetate to render D-~propyl-8~-methylmercaptomethylergoline (pergolide).
The above-noted U.S.patent discloses that various salts of pergolide may be prepared including acid addition salts of inorganic acids such as hydro-chloric, nitric, phosphoric and sulfuric acids as well as salts derived from nontoxic organic acids. Only pharmaceutically-acceptable salts are of value in the present invention and such salts thus include sulfate, nitrate, phosphate, acetate, propionate, caprylate, o~alate, m~lonate, phenylacetate, citrate, lactate, malate, tartrate, maleate, methanesulfonate, toluene-sulfonate and the like. For purposes of the present invention, a preerred salt is the methanesulfonate salt, prepared by treating D-6-_-propyl-8~-methyl-mercaptomethylergoline with methanesulfonic acid to yield D-6-n-propyl-8~-methylmercaptomethylergoline methanesulfonate or simply pergolide mesylate.
It has been found that pharmaceutical composi-tions of pergolide or pharmaceutically-acceptable salts thereof may be stabilized to decomposition by light by the addition to said composition of a stabilizing agent selected from polyvinylpyrrolidone, ~-tocopherol suc-cinate or propyl gallate. Polyvinylpyrrolidone (also known as povidone or PVP~ is a commercially available 1 3 ~
polymer of l-ethenyl-2-pyrrolidinone which has been used in the past as a pharmaceutic aid as a dispersing or suspending agent. ~-Tocopherol succinate is vitamin E
acid succinate whic~ may be prepared by treating ~-tocopherol with succinic anhydride in pyridine. SeeU.S. Patent 2,680,749 of J.D. Cawley et al., issued June 8, 1954. ~-Tocopherol succinate is also a commer-cially available product. ~i~ewise propyl gallate (i.e., 3,4,5-trihydroxy~enzoic acid propyl ester) is a commercially available product or may be readily prepared by known methodologies. Preferably, the 6tabilizing agent used in the present invention is polyvinylpyrrolidone.
For purposes of the present invention, one or more (preferably one) of the stabilizing agents disclosed herein is present in the pharmaceutical composition ;i.n an amount sufficient to effect stabil-ization to decomposition by light of said composition.
For polyvinylpyrrolidone this amount may vary from 0.3 to 2 percent by weight of the total composition and is preferably 0.5 to 1.5 percent by weight of the total composition. For ~-tocopherol succinate and propyl gallate, this amount may vary from 0.15 to 0.7 percent by weight of the total composition and is preferably 0.3 to 0.5 percent by weight of the total composition. The precise amount of stabilizing agent to be used in a particular composition will, of course, vary depending upon the ultimate size of the dosage form, the specific ,! , ,',' .\ , ~ 3 ~ 3 dosage form chosen, the amount of pexgolide present in the dosage form, and the like. Suffice it to say that the pharmaceutical composition will contain the stabil-izing agent in an amount sufficient to effect stabiliza-tion to decomposition by light of said composition.
That is, the composition will be less readily decomposed by light when one o the stabilizing agents disclosed herein is incorporated with said composition (i.e., will be stabiliæed to decomposition by light).
Further, the pharmaceutical compositions which are stabilized to decomposition by light contain a therapeutically efective amount of pergolide or a salt thereof. As used herein, the term "therapeutically effective" refers to that amount of pergolide or a salt thereof sufficient to deliver, in single or divided doses, 0.01 to 6 milligrams (mg) of pergolide per day to the subject being treated. In a preferred embodi-ment, when pergolide mesylate is the pergolide salt in the composition, it is present in an amount sufficient to deliver, in single or divided doses, 0.01 to 8 mg of pergolide per day to the subject being treated.
The skilled artisan will readily recognize that the therapeutically efective amount may vary widely partic-ularly where the route of administration and the partic-ular salt or free base being employed are considerations.Of course, other factors such as the weight or age of the subject being treated as well as the time, frequency and specific pharmaceutical formulation employed in the administration are to be considered in determining the therapeutically effective amount in a given situation.
This amount may be readily ascertained in a particular instance by the skilled artisan utilizing conventional dose titration techniques.
The pharmaceutical compositions of pergolide or a salt thereof stabilized to decomposition by light are preferably compositions for oral administration.
Such compositions include any of the conventional solid or liquid dosage forms such as, for example, tablets, capsules, powders, suspensions, and the like including any sustained release preparations thereof. In addition to pergolide (or a salt thereof) and stabilizing agent, the pharmaceutical compositions of the present invention for oral administration utiliæe pharmaceutically accept-able excipients including, but not limited to, diluents, carriers, lubricants and the like such as glucose, lactose, sucrose, corn and potato starch, microcrystal-line cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, powdered gum tragacanth, gelatin, alginic acid, agar, stearic acid, sodium, calcium and magne~ium stearates, sodium lauryl sulfate, sodium citrate, calcium carbonate, dicalcium phosphate among others; as well as various buffering agents, surfactants, emulsifiers, dispersing agents, flavoring agents and the like.
Preparation of the pharmaceutical compositions disclosed herein are readily achieved by one skilled in the art. Further, the skilled artisan will appreciate 1 3 1 8 2 ~ 3 that the ultimate pharmaceutical composition may be provided in multiple or discrete, unit dose fashion with the latter being preferred. In addition to the.informa-tion provided herein pertinent to the preparation of the pharmaceutical compositions of the invention, further reference may be obtained from standard treatises such as Remin~ton's Pharmaceutical Sciences, Seventeenth Edition, Mack Publishing Co., Easton, PA. (1985).
The invention will now be illustrated by the following examples which shall not be construed as a limitation thereon.
Example 1 Table I depicts tablet formulations containing pergolide mesylate and one of the following stabilizing agents: polyvinylpyrrolidone (composition numbers 1 and 2); ~-tocopherol succinate (composition number 3); and propyl gallate (composition number 4).
Composition number 5 is a control where no stabilizing agent was incorporated into the formulation.
1 3 ~
Table Ia Composition No.
Inqredients 1 2 3 4 5 Pergolide mesylate0.035 0.0350.035 0.035 0.035 Polyvinylpyrrolidone 4.0 4.0 -- -- --~-tocopherol succinate -- -- 1.0 -- --Propyl gallate -- -- -- 1.0 --Lactose 294.3 288.3291.3 291.3 298.3 Iron oxide yellow 0.13 0.13 0.13 0.13 0.13 Crosc:armellose sodium -- 6.0 6.0 6.0 --Magnesium stearate1.535 1.5351.535 1.75 1.535 15 a All amounts shown are in milligrams These formulations and the compressed tablets made therefrom were prepared as follows. The lactose, iron oxide yellow and`croscarmellose sodium were blended 20 together and granulated with a hydroalcoholic solution of pergolide mesylate and the selected stabilizing agent (i.e., polyvinylpyrrolidone, a-tocopherol succinate or propyl gallate). The resultant granulation was dried, screened and blended with magnesium stearate and com-25 pressed into tablets weighing 300 mg each~
Tablets from each of the five compositionsshown in Table I were exposed to fluorescent lights placed at a height of six inches from the tablets and maintained for seven days. However, prior to exposure, 30 sample tablets from each of the five composition . batches were assayed for pergolide content by high performance liquid chromatography (HPLC) as follows.
1 3 ~
X-~378 -9-One tablet (or the weight of ground composite tablets equivalent to the average weight of one tablet) was dissolved in a mixture of methanol and 0.1 normal HCl (80:20, respectively) by shaking for one hour. The resulting mixture was centrifuged and the cleax super-natant was sampled (and further diluted according to tablet potency) and the samples were ru~ on HPLC. The amount of pergolide per tablet was determined by com-paring the area under the pergolide peak with skandard peak areas obtai~ed using known dilutions of pergolide mesylate reference standard.
After exposure to light for seven days, the exposed tahlets were again assayed for pergolide content so as to determine the amount of decomposition which occurred during that period of time. The results are shown in Table II wherein Assay I refers to the tablet assay prior to exposure to light and Assay II refers to the assay of the tablets after exposure to light for seven days.
Table IIa Composition No.
Assay_No. 1 2 3 4 5 I 18.6 20.2 21.6 28.3 22.0 II 19.4 18.5 20,4 25.6 13.9 Percent Change +4.3 -8.4 -5.6 -9.5 -36.8 a All amounts shown (except for percent change) are in micrograms , ,:
~3~ ~2~
As can be seen from the data presented in Table II, all compositions having a stabilizing agent included in the formulation all exhibited less than a 10 percent decrease in pergolide content following seven days of exposure to the fluorescent lighting.
By contrast, composition number 5 which did not contain a stabilizing agent exhibited a decrease in pergolide content of nearly 37 percent.
Example 2 Tablets of pergolide mesylate having the following compositions (amounts shown in milligrams) were prepared as described in Example 1.
Composition No.
Ingredients 6 7 Pergolide mesylate 0.0705 0.0705 20 Polyvinylpyrrolidone 4.0 --Lactose 288.0 292.0 Iron oxide yellow 0.13 0.13 Croscarmellose sodium 6.0 6.0 Magnesium stearate 1.75 1.75 Again, following the procedures of Exa~ple 1, samples of tablets from batches of composition numbers 6 and 7 were exposed to fluorescent lights placed at a height of six inches and maintained for seven days.
The same assays were performed as described in the previous example (i.e., assays for pergolide content ~. 3 ~ 3 before and after light exposure) as well as an assay for pergolide sulfoxide content (a major oxidation product of pergolide) before and after exposure to light. The assay for pergolide sulfoxide was conducted essentially as described above for pergolide (i.e., HPLC) but using a pergolide sulfoxide reference standard. The results of the assays for pergolide con-tent a~d pergolide sulfoxide content are set forth in Tables III and IV, respectively.
Table IIIa Pergolide Content Composition No.
15 AsRav No. 6 7 I 47.1 50.3 II 44.1 39.0 Percent Change -6.4 -22.5 a All amounts shown (except for percent change) are expressed in micrograms.
~ 3 ~ 3 Table IVa Pergol de Sulfoxide Content Composition No.
5 Assay No. 6 7 ; I 11.6 1.99 II 11.1 13.1 .
Percent Change -4.3 +558 a All amounts shown (except for percent change) are expressed as a percent of pergolide concentration.
The data shown in Table III again clearly depict that compositions of pergolide mesylate containing, in this case, polyvinylpyrrolidone are stabilized to decomposition by light compared to a composition not containing the stabilizing agent. The results of the pergolide sulfoxide assays (Table IV) show a significant increase in sulfoxide content (as the product of decomposition) for formulation number 7. The data for composition number 6 are believed to be artifactual owing to the atypically high amount of pergolide sulfoxide present in the composition prior to exposure to the fluorescent lighting.
STABILIZED PERGOLIDE COMPOSITIONS
This invention relates to pharmaceutical compositions containing pergolide.
Pergolide is an ergoline derivative which exhibits potent dopaminergic agonist activity and also decreases plasma prolactin concentrations. The com~ound is thus useful in treating physiological manifestations associated with hyperprolactinemia. Chemically, pergolide is D-6-n-propyl-8~-methylmercaptomethyl-ergoline (See U.S. Patent 4,166,1823.
It has been found that pergolide decomposes upon exposure to light (apparently to a sulfoxide species) thus making it necessary to handle the compound and store the ultimate dosage form in light-controlled environments so as to avoid a demonstrable drop in potency of the therapeutic agent. In order to retard this drop in potency, certain stabilizing agents have been incorporated into pharmaceutical compositions containing pergolide which surprisingly reduce the decomposition of this compound when exposed to light.
The present invention is directed to a pharmaceutical composition o pergolide or pharma-ceutically-acceptable salts thereof stabilized to decomposition by light. Said composition comprises pergolide or pharmaceutically-acceptable salts thereof, a stabilizing agent selected from polyvinylpyrrolidone, a-tocopherol succinate and propyl gallate in an amount , l 3 1 ~
X-637~ -2-sufficient to effect stabilization to decomposition by light, and one or more pharmaceutically acceptable excipients.
Also provided is a method of stabilizing a pharmaceutical composition of pergolide or pharma-ceutical-acceptable salts thereof to decomposition by light. The method comprises incorporating into said pharmaceutical composition, in addition to the pergolide or pharmaceutically-acceptable salts thereof, as well a~ the pharmaceutically acceptable excipients normally present, a stabilizing agent selected from polyvinyl-pyrrolidone, ~-tocopherol succinate and propyl gallate in an amount sufficient to effect stabilization to decomposition by light. Normally, each unit dosage such as a tablet or capsule will contain sufficient pergolide or salt thereof to be therapeutically-effective.
Pergolide (i.e., D-6-n-propyl-8~-methyl-mercaptomethylergoline) may be prepared as described in U.S. Patent 4,166,182. Briefly, methyl dihydrolysergate can be treated with cyanogen bromide in an inert solvent such as chloroform, methylene dichloride, toluene, DMF
and the like to form D-6-cyano-8~-methoxycarbonyl ergoline. The cyanide group is then readily removed as by zinc dust in acetic acid forming a secondary amine function at N-6 which can then be re-alkylated with, for example, N-propyl iodide in an inert, preferably polar solvent such as dimethylformamide or nitromethane at temperatures in the range of 20-50 centigrade (C~. The ester function at C-8 is then reduced by treatmen~ with, if~
~ $~
for example, sodium borohydride in dioxane to formD~6-n-propyl-8~-hydroxymethylergoline which is then re-esterified by treatment with methanesulfonyl chloride in pyridine to form D-6-n-propyl-8~-mesyloxymethyl ergoline. The mesyloxy derivative is then treated with methylmercaptan in dimethyl acetate to render D-~propyl-8~-methylmercaptomethylergoline (pergolide).
The above-noted U.S.patent discloses that various salts of pergolide may be prepared including acid addition salts of inorganic acids such as hydro-chloric, nitric, phosphoric and sulfuric acids as well as salts derived from nontoxic organic acids. Only pharmaceutically-acceptable salts are of value in the present invention and such salts thus include sulfate, nitrate, phosphate, acetate, propionate, caprylate, o~alate, m~lonate, phenylacetate, citrate, lactate, malate, tartrate, maleate, methanesulfonate, toluene-sulfonate and the like. For purposes of the present invention, a preerred salt is the methanesulfonate salt, prepared by treating D-6-_-propyl-8~-methyl-mercaptomethylergoline with methanesulfonic acid to yield D-6-n-propyl-8~-methylmercaptomethylergoline methanesulfonate or simply pergolide mesylate.
It has been found that pharmaceutical composi-tions of pergolide or pharmaceutically-acceptable salts thereof may be stabilized to decomposition by light by the addition to said composition of a stabilizing agent selected from polyvinylpyrrolidone, ~-tocopherol suc-cinate or propyl gallate. Polyvinylpyrrolidone (also known as povidone or PVP~ is a commercially available 1 3 ~
polymer of l-ethenyl-2-pyrrolidinone which has been used in the past as a pharmaceutic aid as a dispersing or suspending agent. ~-Tocopherol succinate is vitamin E
acid succinate whic~ may be prepared by treating ~-tocopherol with succinic anhydride in pyridine. SeeU.S. Patent 2,680,749 of J.D. Cawley et al., issued June 8, 1954. ~-Tocopherol succinate is also a commer-cially available product. ~i~ewise propyl gallate (i.e., 3,4,5-trihydroxy~enzoic acid propyl ester) is a commercially available product or may be readily prepared by known methodologies. Preferably, the 6tabilizing agent used in the present invention is polyvinylpyrrolidone.
For purposes of the present invention, one or more (preferably one) of the stabilizing agents disclosed herein is present in the pharmaceutical composition ;i.n an amount sufficient to effect stabil-ization to decomposition by light of said composition.
For polyvinylpyrrolidone this amount may vary from 0.3 to 2 percent by weight of the total composition and is preferably 0.5 to 1.5 percent by weight of the total composition. For ~-tocopherol succinate and propyl gallate, this amount may vary from 0.15 to 0.7 percent by weight of the total composition and is preferably 0.3 to 0.5 percent by weight of the total composition. The precise amount of stabilizing agent to be used in a particular composition will, of course, vary depending upon the ultimate size of the dosage form, the specific ,! , ,',' .\ , ~ 3 ~ 3 dosage form chosen, the amount of pexgolide present in the dosage form, and the like. Suffice it to say that the pharmaceutical composition will contain the stabil-izing agent in an amount sufficient to effect stabiliza-tion to decomposition by light of said composition.
That is, the composition will be less readily decomposed by light when one o the stabilizing agents disclosed herein is incorporated with said composition (i.e., will be stabiliæed to decomposition by light).
Further, the pharmaceutical compositions which are stabilized to decomposition by light contain a therapeutically efective amount of pergolide or a salt thereof. As used herein, the term "therapeutically effective" refers to that amount of pergolide or a salt thereof sufficient to deliver, in single or divided doses, 0.01 to 6 milligrams (mg) of pergolide per day to the subject being treated. In a preferred embodi-ment, when pergolide mesylate is the pergolide salt in the composition, it is present in an amount sufficient to deliver, in single or divided doses, 0.01 to 8 mg of pergolide per day to the subject being treated.
The skilled artisan will readily recognize that the therapeutically efective amount may vary widely partic-ularly where the route of administration and the partic-ular salt or free base being employed are considerations.Of course, other factors such as the weight or age of the subject being treated as well as the time, frequency and specific pharmaceutical formulation employed in the administration are to be considered in determining the therapeutically effective amount in a given situation.
This amount may be readily ascertained in a particular instance by the skilled artisan utilizing conventional dose titration techniques.
The pharmaceutical compositions of pergolide or a salt thereof stabilized to decomposition by light are preferably compositions for oral administration.
Such compositions include any of the conventional solid or liquid dosage forms such as, for example, tablets, capsules, powders, suspensions, and the like including any sustained release preparations thereof. In addition to pergolide (or a salt thereof) and stabilizing agent, the pharmaceutical compositions of the present invention for oral administration utiliæe pharmaceutically accept-able excipients including, but not limited to, diluents, carriers, lubricants and the like such as glucose, lactose, sucrose, corn and potato starch, microcrystal-line cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, powdered gum tragacanth, gelatin, alginic acid, agar, stearic acid, sodium, calcium and magne~ium stearates, sodium lauryl sulfate, sodium citrate, calcium carbonate, dicalcium phosphate among others; as well as various buffering agents, surfactants, emulsifiers, dispersing agents, flavoring agents and the like.
Preparation of the pharmaceutical compositions disclosed herein are readily achieved by one skilled in the art. Further, the skilled artisan will appreciate 1 3 1 8 2 ~ 3 that the ultimate pharmaceutical composition may be provided in multiple or discrete, unit dose fashion with the latter being preferred. In addition to the.informa-tion provided herein pertinent to the preparation of the pharmaceutical compositions of the invention, further reference may be obtained from standard treatises such as Remin~ton's Pharmaceutical Sciences, Seventeenth Edition, Mack Publishing Co., Easton, PA. (1985).
The invention will now be illustrated by the following examples which shall not be construed as a limitation thereon.
Example 1 Table I depicts tablet formulations containing pergolide mesylate and one of the following stabilizing agents: polyvinylpyrrolidone (composition numbers 1 and 2); ~-tocopherol succinate (composition number 3); and propyl gallate (composition number 4).
Composition number 5 is a control where no stabilizing agent was incorporated into the formulation.
1 3 ~
Table Ia Composition No.
Inqredients 1 2 3 4 5 Pergolide mesylate0.035 0.0350.035 0.035 0.035 Polyvinylpyrrolidone 4.0 4.0 -- -- --~-tocopherol succinate -- -- 1.0 -- --Propyl gallate -- -- -- 1.0 --Lactose 294.3 288.3291.3 291.3 298.3 Iron oxide yellow 0.13 0.13 0.13 0.13 0.13 Crosc:armellose sodium -- 6.0 6.0 6.0 --Magnesium stearate1.535 1.5351.535 1.75 1.535 15 a All amounts shown are in milligrams These formulations and the compressed tablets made therefrom were prepared as follows. The lactose, iron oxide yellow and`croscarmellose sodium were blended 20 together and granulated with a hydroalcoholic solution of pergolide mesylate and the selected stabilizing agent (i.e., polyvinylpyrrolidone, a-tocopherol succinate or propyl gallate). The resultant granulation was dried, screened and blended with magnesium stearate and com-25 pressed into tablets weighing 300 mg each~
Tablets from each of the five compositionsshown in Table I were exposed to fluorescent lights placed at a height of six inches from the tablets and maintained for seven days. However, prior to exposure, 30 sample tablets from each of the five composition . batches were assayed for pergolide content by high performance liquid chromatography (HPLC) as follows.
1 3 ~
X-~378 -9-One tablet (or the weight of ground composite tablets equivalent to the average weight of one tablet) was dissolved in a mixture of methanol and 0.1 normal HCl (80:20, respectively) by shaking for one hour. The resulting mixture was centrifuged and the cleax super-natant was sampled (and further diluted according to tablet potency) and the samples were ru~ on HPLC. The amount of pergolide per tablet was determined by com-paring the area under the pergolide peak with skandard peak areas obtai~ed using known dilutions of pergolide mesylate reference standard.
After exposure to light for seven days, the exposed tahlets were again assayed for pergolide content so as to determine the amount of decomposition which occurred during that period of time. The results are shown in Table II wherein Assay I refers to the tablet assay prior to exposure to light and Assay II refers to the assay of the tablets after exposure to light for seven days.
Table IIa Composition No.
Assay_No. 1 2 3 4 5 I 18.6 20.2 21.6 28.3 22.0 II 19.4 18.5 20,4 25.6 13.9 Percent Change +4.3 -8.4 -5.6 -9.5 -36.8 a All amounts shown (except for percent change) are in micrograms , ,:
~3~ ~2~
As can be seen from the data presented in Table II, all compositions having a stabilizing agent included in the formulation all exhibited less than a 10 percent decrease in pergolide content following seven days of exposure to the fluorescent lighting.
By contrast, composition number 5 which did not contain a stabilizing agent exhibited a decrease in pergolide content of nearly 37 percent.
Example 2 Tablets of pergolide mesylate having the following compositions (amounts shown in milligrams) were prepared as described in Example 1.
Composition No.
Ingredients 6 7 Pergolide mesylate 0.0705 0.0705 20 Polyvinylpyrrolidone 4.0 --Lactose 288.0 292.0 Iron oxide yellow 0.13 0.13 Croscarmellose sodium 6.0 6.0 Magnesium stearate 1.75 1.75 Again, following the procedures of Exa~ple 1, samples of tablets from batches of composition numbers 6 and 7 were exposed to fluorescent lights placed at a height of six inches and maintained for seven days.
The same assays were performed as described in the previous example (i.e., assays for pergolide content ~. 3 ~ 3 before and after light exposure) as well as an assay for pergolide sulfoxide content (a major oxidation product of pergolide) before and after exposure to light. The assay for pergolide sulfoxide was conducted essentially as described above for pergolide (i.e., HPLC) but using a pergolide sulfoxide reference standard. The results of the assays for pergolide con-tent a~d pergolide sulfoxide content are set forth in Tables III and IV, respectively.
Table IIIa Pergolide Content Composition No.
15 AsRav No. 6 7 I 47.1 50.3 II 44.1 39.0 Percent Change -6.4 -22.5 a All amounts shown (except for percent change) are expressed in micrograms.
~ 3 ~ 3 Table IVa Pergol de Sulfoxide Content Composition No.
5 Assay No. 6 7 ; I 11.6 1.99 II 11.1 13.1 .
Percent Change -4.3 +558 a All amounts shown (except for percent change) are expressed as a percent of pergolide concentration.
The data shown in Table III again clearly depict that compositions of pergolide mesylate containing, in this case, polyvinylpyrrolidone are stabilized to decomposition by light compared to a composition not containing the stabilizing agent. The results of the pergolide sulfoxide assays (Table IV) show a significant increase in sulfoxide content (as the product of decomposition) for formulation number 7. The data for composition number 6 are believed to be artifactual owing to the atypically high amount of pergolide sulfoxide present in the composition prior to exposure to the fluorescent lighting.
Claims (10)
1. A pharmaceutical composition stabilized to decomposition by light comprising as an active ingredient pergolide or pharmaceutically-acceptables salt thereof, a stabilizing agent selected from poly-vinylpyrrolidone, .alpha.-tocopherol succinate and propyl gallate in an amount sufficient to effect stabilization to decomposition by light, and one or more other pharm-aceutically acceptable excipients.
2. A pharmaceutical composition of claim 1, wherein the pharmaceutically-acceptable salt of pergolide is pergolide mesylate.
3. A pharmaceutical composition of claim 1 or 2, wherein the stabilizing agent is polyvinyl-pyrrolidone.
4. A pharmaceutical composition of claim 1 or 3 wherein the polyvinylpyrrolidone is present in said composition in an amount of from 0.3 to 2 percent by weight of the total composition.
5. A pharmaceutical composition of claim 4, wherein the polyvinylpyrrolidone is present in said composition in an amount of from 0.5 to 1.5 percent by weight of the total composition.
6. A method of stabilizing a pharmaceutical composition of pergolide or pharmaceutically-acceptable salts thereof to decomposition by light comprising incorporating into said pharmaceutical composition, in addition to any pharmaceutically-acceptable excipient normally present and said pergolide or pharmaceutically-acceptable salts thereof, a stabilizing agent selected X-6378-(EPO) -14-from polyvinylpyrrolidone, .alpha.-tocopherol succinate and propyl gallate in an amount sufficient to effect stabilization to decomposition by light.
7. A method of claim 6 wherein the pergolide is present as pergolide mesylate.
8. A method of claim 6 or 7 wherein the stabilizing agent is polyvinylpyrrolidone.
9. A method of claim 8 wherein the poly-vinylpyrrolidone is present in an amount of from 0.3 to 2 percent by weight of the total composition.
10. A method of claim 9 wherein the poly vinylpyrrolidone is present in an amount of from 0.5 to 1.5 percent by weight of the total composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/112,360 | 1987-10-26 | ||
| US07/112,360 US4797405A (en) | 1987-10-26 | 1987-10-26 | Stabilized pergolide compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1318253C true CA1318253C (en) | 1993-05-25 |
Family
ID=22343489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000580595A Expired - Fee Related CA1318253C (en) | 1987-10-26 | 1988-10-19 | Stabilized pergolide compositions |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4797405A (en) |
| EP (1) | EP0314387B1 (en) |
| JP (1) | JP2747303B2 (en) |
| KR (1) | KR960013284B1 (en) |
| AT (1) | ATE79258T1 (en) |
| AU (1) | AU611494B2 (en) |
| CA (1) | CA1318253C (en) |
| DE (1) | DE3873688T2 (en) |
| DK (1) | DK174831B1 (en) |
| ES (1) | ES2042760T3 (en) |
| GR (1) | GR3005784T3 (en) |
| HU (1) | HU200691B (en) |
| IE (1) | IE61960B1 (en) |
| IL (1) | IL88087A (en) |
| NZ (1) | NZ226650A (en) |
| PH (1) | PH25575A (en) |
| ZA (1) | ZA887805B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114948A (en) * | 1989-10-19 | 1992-05-19 | Eli Lilly And Company | Stabilized pergolide compositions |
| US6572879B1 (en) * | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
| US6623752B1 (en) | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
| DE19626621A1 (en) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Plaster for transdermal application of pergolide |
| US7351429B1 (en) | 1999-11-11 | 2008-04-01 | Kyorin Pharmaceutical Co., Ltd. | Oral solid preparation |
| EP1318813A4 (en) * | 2000-08-08 | 2005-09-07 | Teva Pharma | Stable pergolide mesylate and process for making same |
| US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
| DE10341317B4 (en) * | 2003-09-03 | 2008-10-23 | Axxonis Pharma Ag | Transdermal therapeutic system (TTS) for administration of ergoline compounds except pergolide |
| DE10053397A1 (en) * | 2000-10-20 | 2002-05-02 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
| DE10066158B4 (en) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Use of a transdermal therapeutic system for the treatment of Restless Legs Syndrome |
| DE10064453A1 (en) * | 2000-12-16 | 2002-07-04 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
| KR20040088519A (en) | 2002-02-22 | 2004-10-16 | 뉴 리버 파마슈티칼스, 인크. | Active Agent Delivery Systems and Methods for Protecting and Administering Active Agents |
| AU2003215461A1 (en) * | 2002-03-26 | 2003-10-08 | Bernard Charles Sherman | Stable tablets comprising pergolide mesylate |
| KR101302118B1 (en) * | 2011-04-22 | 2013-08-30 | 한림대학교 산학협력단 | Enhancing method for transduction of fusion protein by adding pergolide |
| WO2019234069A1 (en) * | 2018-06-08 | 2019-12-12 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising pergolide |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2680749A (en) * | 1951-12-01 | 1954-06-08 | Eastman Kodak Co | Water-soluble tocopherol derivatives |
| US3864469A (en) * | 1967-12-16 | 1975-02-04 | Hoechst Ag | Xanthines in pharmaceutical preparations and for stabilization of vitamins |
| US4473565A (en) * | 1976-05-13 | 1984-09-25 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
| JPS5399316A (en) * | 1977-02-04 | 1978-08-30 | Sanpo Seiyaku Kk | Stbilyzing method of leserpine preparation |
| AT362051B (en) * | 1977-04-05 | 1981-04-27 | Sandoz Ag | METHOD FOR PRODUCING INJECTION PREPARATIONS |
| JPS542316A (en) * | 1977-06-07 | 1979-01-09 | Yamanouchi Pharmaceut Co Ltd | Solid pharmaceutical composition containing nifedipene |
| JPS5446837A (en) * | 1977-09-19 | 1979-04-13 | Kanebo Ltd | Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same |
| US4166182A (en) * | 1978-02-08 | 1979-08-28 | Eli Lilly And Company | 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
| US4202979A (en) * | 1979-01-11 | 1980-05-13 | Eli Lilly And Company | 6-Ethyl(or allyl)-8-methoxymethyl or methylmercaptomethylergolines and related compounds |
| US4329366A (en) * | 1979-11-08 | 1982-05-11 | Johnson & Johnson Products, Inc. | Topical acylaminophenols |
| DE3136282A1 (en) * | 1981-09-12 | 1983-03-24 | Hoechst Ag | "METHOD FOR STABILIZING PHOTO-UNSTABLE MEDICINAL PRODUCTS AND STABILIZED MEDICAL PREPARATIONS" |
| JPS58105913A (en) * | 1981-12-18 | 1983-06-24 | Nippon Chemiphar Co Ltd | Nifedipine soft capsule |
| JPS58206533A (en) * | 1982-05-27 | 1983-12-01 | Teijin Ltd | Active type vitamin d3 derivative composition and drug comprising it as active ingredient |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| JPS60155111A (en) * | 1983-10-20 | 1985-08-15 | Hisamitsu Pharmaceut Co Inc | Stable pharmaceutical for external use containing "ketoprofen(r)" |
| DE3424553A1 (en) * | 1984-07-04 | 1986-01-09 | Bayer Ag, 5090 Leverkusen | SOLID DRUG PREPARATIONS WITH DIHYDROPYRIDINE AND METHOD FOR THE PRODUCTION THEREOF |
| JPS6176416A (en) * | 1984-09-20 | 1986-04-18 | Fujimoto Seiyaku Kk | Activated type vitamin d3 derivative composition for encapsulation |
| JPS6270317A (en) * | 1985-09-24 | 1987-03-31 | Sawai Seiyaku Kk | Drug preparation containing activated vitamin d3 |
| DE3814521A1 (en) * | 1987-05-07 | 1988-11-17 | Sandoz Ag | NEW APPLICATION OF DOPAMINE RECEPTOR AGONISTS |
-
1987
- 1987-10-26 US US07/112,360 patent/US4797405A/en not_active Expired - Lifetime
-
1988
- 1988-10-19 ZA ZA887805A patent/ZA887805B/en unknown
- 1988-10-19 IL IL88087A patent/IL88087A/en not_active IP Right Cessation
- 1988-10-19 CA CA000580595A patent/CA1318253C/en not_active Expired - Fee Related
- 1988-10-20 AU AU24080/88A patent/AU611494B2/en not_active Expired
- 1988-10-20 DE DE8888309848T patent/DE3873688T2/en not_active Expired - Lifetime
- 1988-10-20 DK DK198805831A patent/DK174831B1/en not_active IP Right Cessation
- 1988-10-20 ES ES88309848T patent/ES2042760T3/en not_active Expired - Lifetime
- 1988-10-20 EP EP88309848A patent/EP0314387B1/en not_active Expired - Lifetime
- 1988-10-20 HU HU885422A patent/HU200691B/en unknown
- 1988-10-20 NZ NZ226650A patent/NZ226650A/en unknown
- 1988-10-20 KR KR1019880013656A patent/KR960013284B1/en not_active IP Right Cessation
- 1988-10-20 AT AT88309848T patent/ATE79258T1/en not_active IP Right Cessation
- 1988-10-20 JP JP63267000A patent/JP2747303B2/en not_active Expired - Lifetime
- 1988-10-21 PH PH37714A patent/PH25575A/en unknown
- 1988-10-21 IE IE319988A patent/IE61960B1/en not_active IP Right Cessation
-
1992
- 1992-09-24 GR GR920402106T patent/GR3005784T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2042760T3 (en) | 1993-12-16 |
| DE3873688D1 (en) | 1992-09-17 |
| IL88087A (en) | 1992-09-06 |
| EP0314387B1 (en) | 1992-08-12 |
| KR960013284B1 (en) | 1996-10-02 |
| IE883199L (en) | 1989-04-26 |
| HU200691B (en) | 1990-08-28 |
| DE3873688T2 (en) | 1993-03-11 |
| HUT48462A (en) | 1989-06-28 |
| US4797405A (en) | 1989-01-10 |
| IL88087A0 (en) | 1989-06-30 |
| AU2408088A (en) | 1989-04-27 |
| JPH01146821A (en) | 1989-06-08 |
| GR3005784T3 (en) | 1993-06-07 |
| JP2747303B2 (en) | 1998-05-06 |
| AU611494B2 (en) | 1991-06-13 |
| NZ226650A (en) | 1990-08-28 |
| EP0314387A1 (en) | 1989-05-03 |
| KR890006238A (en) | 1989-06-12 |
| DK583188A (en) | 1989-04-27 |
| PH25575A (en) | 1991-08-08 |
| ATE79258T1 (en) | 1992-08-15 |
| DK583188D0 (en) | 1988-10-20 |
| DK174831B1 (en) | 2003-12-08 |
| IE61960B1 (en) | 1994-11-30 |
| ZA887805B (en) | 1990-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1318253C (en) | Stabilized pergolide compositions | |
| US4743450A (en) | Stabilized compositions | |
| CA1147651A (en) | Sustained release pharmaceutical compositions | |
| KR100402570B1 (en) | Injectable quinolone formulations | |
| US5114948A (en) | Stabilized pergolide compositions | |
| US4301146A (en) | Stabilization of 16-oxygenated prostanoic acid derivatives | |
| CA1273877A (en) | Substantially dry tablet formulation for quinoline carboxylic acid antibacterial agents | |
| EP0026671A1 (en) | Novel ergoline derivatives, compositions containing them, their preparation and use as pharmaceuticals | |
| CA2290070A1 (en) | Salts of aromatic sulphonic acids | |
| US6689384B2 (en) | Stable pergolide mesylate and process for making same | |
| US5266581A (en) | Solid composition containing dihydropyridine, PVP and PVPP | |
| CA1043260A (en) | Water soluble lipophilic liquid fatty acid salts comprising therapeutic agents having a tertiary nitrogen capable of being protonated | |
| EP1391453B1 (en) | Pyroglutamic acid salt of amlodipine | |
| US5069911A (en) | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions | |
| EP0860169A2 (en) | Compositions for oral administration containing pyridazinone compounds | |
| US20040029931A1 (en) | Organic acid salt of amlodipine | |
| JPH0678227B2 (en) | Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-containing formulations, stabilization method and stabilized formulations | |
| EP0753512B1 (en) | N,N,-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamin] dimaleate salt | |
| EP1549616A1 (en) | Organic acid salt of amlodipine | |
| KR100765464B1 (en) | Pharmaceutical compositions comprising amlodipine maleate and method thereof | |
| CA3077296A1 (en) | Novel crystalline form betrixaban maleate | |
| WO2004011434A1 (en) | Organic acid salt of amlodipine | |
| CA3107017A1 (en) | Crystalline forms of tenofovir alafenamide | |
| KR100266908B1 (en) | A stability-improved composite for misoprostol and the preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |